Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.37 |
| ▸ | TTPA | P49638 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11857451 | 0.84 | CYP3A4 (0.42) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL12434165 | 0.83 | PTGS1 (0.40) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL27855951 | 0.82 | PTGS1 (0.45) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| Apc-100 SCHEMBL633424 | 0.82 | CYP3A4 (0.64) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL1284918 | 0.79 | HSP90AA1 (0.42) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL14283913 | 0.78 | CYP3A4 (0.39) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL14283903 | 0.78 | AKT1 (0.39) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL1285776 | 0.78 | MALT1 (0.39) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL5838918 | 0.78 | PDE4D (0.36) | PTGS2CYP3A4PTGS1CYP1A2TSHR | |
| SCHEMBL1285831 | 0.78 | CYP3A4 (0.48) | PTGS2CYP3A4PTGS1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | claimed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | claimed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | claimed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | claimed |
| WO-2005032544-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS, INC. (US) | 2005-04-14 | — | — | WO | claimed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | claimed |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | BIOELECTRON TECHNOLOGY CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | GALILEO PHARMACEUTICALS INC. | 2013-10-10 | — | — | US | disclosed |
| US-20060106014-A1 | Methods for treating diabetes | ELI LILLY AND COMPANY | 2006-05-18 | — | — | US | disclosed |
| WO-2006044556-A2 | DUAL INHIBITORS OF LIPOXYGENASE FOR TREATING DIABETES | GALILEO PHARMACEUTICALS, INC. (US) | 2006-04-27 | — | — | WO | disclosed |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | EDISON PHARMACEUTICALS, INC. | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106014-A1 | Methods for treating diabetes | ALOX5, ALOX15, ALOX15B | PTGS2 60/4885CYP3A4 689/4885PTGS1 89/4885 |
| US-20050065099-A1 | Alzheimer's disease; Parkinson's disease; brain disorders; antiepileptic agents; amyotrophic lateral sclerosis; vision defects | CLN6, LDHA, NLN | PTGS2 3398/4885CYP3A4 2690/4885PTGS1 3200/4885 |
| US-20160324823-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | PTGS2 2651/4885CYP3A4 3089/4885PTGS1 2790/4885 |
| US-20130267538-A1 | TREATMENT OF MITOCHONDRIAL DISEASES | NLN, FH, MFN2 | PTGS2 2651/4885CYP3A4 3089/4885PTGS1 2790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.